Previous 10 | Next 10 |
NLS Pharma ( NASDAQ: NLSP ) said it had received a notification letter from the Nasdaq stating that it had regained compliance with the minimum bid price requirement. NLS was notified by Nasdaq of its failure to maintain a minimum bid price of $1 per share for 30 consecutive busin...
Management to Discuss Pipeline Goals and Development Strategies across four Preclinical and 2 Clinical Programs across Multiple Central Nervous System (CNS) Disorders NLS to Webcast its R&D Day Event Tuesday, January 31 at 10:00am EST ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2...
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system ...
Hong Kong patent relates to Company's lead product candidate, Mazindol ER (extended-release) use in narcolepsy, idiopathic hypersomnia (IH) and attention deficit hyperactivity disorder (ADHD) Further supports NLS global strategy with key patents now granted in major markets including Hong Ko...
NLS Pharmaceutics ( NASDAQ: NLSP ) said on Tuesday the Israeli Patent Office had granted approval for its lead drug, Mazindol, as a method of treatment for Attention Deficit/Hyperactivity Disorder. This patent will expire in 2037. NLS said it had accelerated ongoing clinical devel...
Israeli patent relates to Mazindol use in attention deficit hyperactivity disorder (ADHD) or related arousal deficits (i.e., uncontrollable sleepiness), use in the treatment of reduced alertness (daytime sleepiness), or excessive daytime sleepiness, such as narcolepsy or idiopathic hypersomnia. ...
Financing provided exclusively by leading healthcare fund BVF Partners L.P. Cash runway potentially secured beyond pivotal studies and NDA submission for Quilience® (Mazindol ER) in narcolepsy ZURICH, SWITZERLAND / ACCESSWIRE / December 14, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NL...
NLS Pharmaceutics ( NASDAQ: NLSP ) said Wednesday it received a notice from Nasdaq, indicating that it was not in compliance with the minimum bid price rule for continued listing. As the 180-day grace period to regain compliance expired, NLS ( NLSP ) received an addi...
Financing provided exclusively by leading healthcare fund BVF Partners L.P. ZURICH, SWITZERLAND / ACCESSWIRE / December 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development o...
ZURICH, SWITZERLAND / ACCESSWIRE / December 7, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
News, Short Squeeze, Breakout and More Instantly...
NLS Pharmaceutics Ltd. Company Name:
NLSP Stock Symbol:
NASDAQ Market:
NLS Pharmaceutics Ltd. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support f...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...